The Long Island Parkinson's Disease Center

长岛帕金森病中心

• 批准号: 6660404
• 负责人: ANDREW FEIGIN
• 金额: $ 11.99万
• 依托单位: FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-30 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6660404
• 关键词: Parkinson's disease; biomarker; chemoprevention; clinical research; clinical trials; cooperative study; human subject; human therapy evaluation; medical outreach /case finding; nervous system disorder therapy; neuroimaging; neuropharmacology; neuroprotectants; patient oriented research

DESCRIPTION (provided by applicant): Parkinson's disease (PD) is a common degenerative neurological disease, affecting approximately 1 million Americans. Advances in the treatment and management of PD over the past ten years have increasingly required general neurologists to seek advice from Movement Disorders specialists in order to optimize PD patient care. With advances in the understanding of the pathophysiology PD, new strategies for slowing the course of PD are emerging. As these therapies have begun to move to clinical trials, patient access to these trials has been and will likely continue to be primarily through PD centers. We have assembled a network of PD specialists in or near Long Island, NY with a combination of practical experience in the management of PD, extensive clinical trial experience, and clinical research excellence related to the development of imaging methods for assessing therapies for PD. With this combination of PD clinical trial and research experience and a very broad population base, we are uniquely positioned to achieve the following Specific Aims: 1) To participate successfully in the planned large-scale simple neuroprotective clinical trial for PD. At North Shore University Hospital (NSUH) we have a long track record of successful completion of clinical trials for PD and of recruitment for clinical research; and 2) To provide expertise regarding potential neuroimaging markers for the planned clinical trial. The functional imaging laboratory at NSUH has focused on the assessment of therapies for PD. Drs. Feigin and Eidelberg are currently funded by NINDS to study issues directly related to the assessment of potential neuroprotective agents for PD and therefore have a unique perspective that may be of benefit for the planning of the future clinical trial. To support our contention that we can successfully achieve these Specific Aims, this application will focus on five areas: 1) The demographics of our catchment area; 2) A description of our current PD patient population and our multidisciplinary PD center; 3) Plans to further enhance recruitment for the planned clinical trial; 4) The experience of our center personnel with all aspects of clinical trial conduct both through multicenter consortiums and independently; and 5) A brief description of our imaging studies of therapies for PD.

描述（由申请人提供）：帕金森氏病（PD）是一种常见的退化性神经系统疾病，影响了约100万美国人。在过去的十年中，PD的治疗和管理进展越来越要求普通神经科医生从运动障碍专家寻求建议，以优化PD患者护理。随着对病理生理PD的理解，新的PD进程的新策略正在出现。由于这些疗法已经开始进行临床试验，因此患者可以使用这些试验，并且可能主要通过PD中心继续进行。我们已经在纽约州长岛或附近组成了一个由PD专家组成的网络，其中包括在PD管理，广泛的临床试验经验以及与评估PD疗法的成像方法相关的临床研究方面的实践经验。通过PD临床试验和研究经验以及非常广泛的人群基础的这种组合，我们在实现以下特定目的方面具有独特的位置：1）成功参与了PD计划的大规模简单神经保护临床试验。在北岸大学医院（NSUH），我们在成功完成PD的临床试验和招募临床研究的临床试验方面有着悠久的记录； 2）为计划的临床试验提供有关潜在神经影像标记的专业知识。 NSUH的功能成像实验室的重点是评估PD的疗法。博士。 Feigin和Eidelberg目前由NINDS资助，用于研究与PD潜在神经保护剂评估直接相关的问题，因此具有独特的观点，这对于计划未来的临床试验可能有益。为了支持我们可以成功实现这些特定目标的论点，该应用将重点放在五个领域：1）我们集水区的人口统计； 2）描述我们当前的PD患者人群和我们的多学科PD中心； 3）计划进一步加强计划的临床试验招聘； 4）我们中心工作人员的经验，具有通过多中心财团和独立的临床试验行为的各个方面的经验； 5）对我们对PD疗法的成像研究的简要描述。